Glenmede Trust CO Na Collegium Pharmaceutical, Inc Transaction History

Glenmede Trust CO Na

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$17.83 - $22.29 $34,679 - $43,354	-1,945 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$15.78 - $20.82 $5,317 - $7,016	-337 Reduced 14.77%	1,945 $40,000
Q2 2020 Aug 14, 2020	SELL	$15.49 - $23.51 $20,384 - $30,939	-1,316 Reduced 36.58%	2,282 $39,000
Q3 2019 Nov 14, 2019	BUY	$10.16 - $13.28 $3,738 - $4,887	368 Added 11.39%	3,598 $41,000
Q2 2019 Aug 13, 2019	BUY	$10.62 - $16.59 $1,731 - $2,704	163 Added 5.31%	3,230 $42,000
Q4 2018 Feb 14, 2019	BUY	$14.78 - $19.68 $39,418 - $52,486	2,667 Added 666.75%	3,067 $52,000
Q2 2018 Aug 15, 2018	BUY	$21.79 - $28.29 $8,716 - $11,316	400 New	400 $10,000

254

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.12B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.